Skip to main content
LG CHEM LTD logo

LG CHEM LTD — Investor Relations & Filings

Ticker · 051910 ISIN · KR7051910008 LEI · 988400IES4EIG7O06940 KO Manufacturing
Open in API
Filings indexed 712 across all filing types
Latest filing 2024-02-01 Report Publication Anno…
Country KR South Korea
Listing KO 051910

About LG CHEM LTD

https://www.lgchem.com/main/index?lang=…

LG Chem is a global science company with a diversified business portfolio in three core areas: Petrochemicals, Advanced Materials, and Life Sciences. The Petrochemicals division operates a vertically integrated system producing basic raw materials and downstream products like PE, ABS, and synthetic rubber. The Advanced Materials division focuses on specialty materials, with a strategic emphasis on becoming a comprehensive global supplier of battery materials. The Life Sciences division is focused on developing innovative new drugs for the global pharmaceutical market. The company prioritizes sustainability and R&D, aiming to develop eco-friendly materials and achieve carbon-neutral growth.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최(안내공시)
Report Publication Announcement Classification · 100% confidence The document is a short announcement (773 characters) regarding the scheduling of an investor relations (IR) meeting. It provides the date, location, and purpose of the meeting, and explicitly directs readers to the company website to access the actual presentation materials. Per the 'Menu vs Meal' rule, since this is an announcement of an event/report rather than the presentation itself, it is classified as a Report Publication Announcement (RPA).
2024-02-01 Korean
기타경영사항(자율공시)(ESG위원회 결과 보고)
Environmental & Social Information Classification · 100% confidence The document is a regulatory filing from LG Chem regarding the results of their ESG Committee meeting. It details internal governance and sustainability management activities (supply chain ESG and compliance risk management). Since it is a specific disclosure of committee results rather than a full ESG report, and it is filed as a 'voluntary disclosure' (자율공시) under regulatory filing standards, it fits best under the Governance Information category.
2024-01-31 Korean
연결재무제표기준영업실적등에대한전망(공정공시)
Regulatory Filings Classification · 95% confidence The document is a 'Fair Disclosure' (공정공시) filing from LG Chem regarding their 2024 financial outlook (revenue targets). It provides forward-looking guidance on sales and business performance metrics. While it mentions an upcoming conference call, the document itself is a formal regulatory disclosure of financial projections, which fits the 'Earnings Release' (ER) category as it serves as the initial announcement of financial expectations and performance targets for the upcoming period.
2024-01-31 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from LG Chem regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the board resolution date. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2024-01-31 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a preliminary earnings release (잠정실적) from LG Chem, detailing quarterly financial performance (revenue, operating profit, net income) for the 4th quarter of 2023. It follows the standard format for an initial earnings announcement, providing key financial highlights rather than a full annual or interim report. It is not a report publication announcement (RPA) because it contains the actual financial data tables, not just a notice of availability. Q4 2023
2024-01-31 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from LG Chem regarding the approval of a new pharmaceutical product (Gemimet SR Tablet) by the Ministry of Food and Drug Safety. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean stock market (KRX). Since it does not fit into specific categories like financial reports, dividends, or M&A, and serves as a general regulatory disclosure of a business development, it is classified as a Regulatory Filing (RNS).
2024-01-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.